Effect of Sublimated Mare Milk Supplement on Gut Microbiome in Psoriasis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03594877|
Recruitment Status : Completed
First Posted : July 20, 2018
Last Update Posted : February 8, 2021
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis||Dietary Supplement: Sublimated mare milk||Not Applicable|
The gut microbiome is believed to play an important role in the immune system regulation, since intestines are the largest lymphoid organ in a human body. Deviations from healthy composition of intestinal flora are associated with various diseases including allergy and autoimmunity. Psoriasis is the one of the long-lasting autoimmune diseases that is characterized by patches on the skin and further health complications throughout the life. However, lack of studies does not allow proper evaluation of role of gut microbiome in psoriasis patients. Therefore, potential interplay between gut microbiome and immune system in psoriasis would be studied in this clinical trial. Particularly, the investigators hypothesize that sublimated mare milk supplement can have an impact on gut immune system and gut microbiome composition in the psoriasis patients.
In this trial, there will be two parallel groups: crossover psoriasis patients (standard treatment first for 3 months, next 3 months standard treatment plus sublimated mare milk supplement) and healthy volunteers group. Subsequently, association of intestinal flora with immune status will be analyzed and compared between these groups.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effectiveness of the Sublimated Mare Milk on the Gut Microbiome in Psoriasis and Healthy Patients|
|Actual Study Start Date :||April 1, 2018|
|Actual Primary Completion Date :||November 30, 2019|
|Actual Study Completion Date :||December 30, 2020|
Experimental: Psoriasis patients
Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
Dietary Supplement: Sublimated mare milk
The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
No Intervention: Healthy volunteers
Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
- Change from baseline in composition of microorganisms in stool after the supplement intervention. [ Time Frame: Baseline, 6 weeks, 12 weeks ]Change in composition of intestinal microbiota will be determined comparing with the baseline results using DNA sequencing Illumina MiSeq System.
- Change from baseline of biomarkers of inflammation in intestines. [ Time Frame: Baseline, 6 weeks, 12 weeks ]The change of immunity will be evaluated from stool specimens according to baseline results of inflammatory cytokines, interleukins, and antibodies. Number of patients, in whom change is statistically significant, will be reported in the results.
- PASI index for psoriasis [ Time Frame: Baseline & 12 weeks ]Dermatological status of PASI index will be evaluated according to the international protocols for treatment of psoriasis (NICE guidance).
- Change from baseline in Vitamin D levels [ Time Frame: Baseline & 12 weeks ]Blood levels of Vitamin D will be compared between baseline and later periods in psoriasis patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03594877
|University Medical Center, Kazakhstan|
|Astana, Kazakhstan, 010000|